Journal of Cystic Fibrosis
Volume 9, Issue 1 , Pages 17-23 , January 2010

Long-term daily high and low doses of azithromycin in children with cystic fibrosis: A randomized controlled trial

Received 3 April 2009 ,Revised 30 August 2009 ,Accepted 10 September 2009.

References 

  1. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD. Lower respiratory tract infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ. 1995;310:1571–1572
  2. Kahn TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 1995;151:1075–1082
  3. Konstan MW, Hilliard KA, Norvell TM, Berger M. Broncho alveolar lavage findings in cystic fibrosis patients with stable clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med. 1994;150:448–454
  4. Jaffé A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol. 2001;31:464–473
  5. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomized trial. Thorax. 2002;57:212–216
  6. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002;360:978–984
  7. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290:1749–1756
  8. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax. 2006;61:895–902
  9. McCormack J, Bell S, Senini S, Walmsley K, Patel K, Wainwright C, et al. Daily versus weekly azithromycin in cystic fibrosis patients. Eur Respir J. 2007;30:487–495
  10. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardization of spirometry. Eur Respir J. 2005;26:319–338
  11. Kabra SK, Alok A, Kapil A, Aggarwal G, Kabra M, Lodha R, et al. Can throat swab after physiotherapy replace sputum or cough swab for identification of microbial pathogens in children with cystic fibrosis?. Indian J Pediatr. 2004;71:15–20
  12. Shwachman H. Cystic fibrosis. In:  Kendig EL,  Chernick V editor. Disorders of respiratory tract in children. 4th edition. London: WB Sounders; 1983;p. 640–661
  13. Govan JRW. Pseudomonas, Stenotrophomonas, Burkholdelia. In:  Collee JG,  Fraser AG,  Marmion BP,  Simmons A editor. th edn. Mackie and McCarttney Practical Medical Microbiology. vol. 14:New York: Churchill Livingstone; 1996;p. 413–424
  14. Jaffé A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet. 1998;351:420
  15. Osika E, Cavillon JM, Chadelat K, Boule M, Fitting C, Tournier G, et al. Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease. J Eur Respir. 1999;14:339–346
  16. Baumann U, King M, App EM, Tai S, König A, Fischer JJ, et al. Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. Can Respir J. 2004;11:151–155
  17. Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2003;(3):CD002203
  18. Steinkamp G, Schmitt-Grohe S, Döring G, Staab D, Pfründer D, Beck G, et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir Med. 2008;102:1643–1653
  19. Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC Macrolide Study Group. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med. 2005;172:1008–1012
  20. Murray TS, Egan M, Kazmierczak BI. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr. 2007;19:83–88
  21. Cigana C, Assael BM, Melotti P. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother. 2007;51:975–981

PII: S1569-1993(09)00123-4

doi: 10.1016/j.jcf.2009.09.001

Journal of Cystic Fibrosis
Volume 9, Issue 1 , Pages 17-23 , January 2010

Article Tools

* Image Usage & Resolution